Issue link: https://www.e-digitaleditions.com/i/819216
research news Tablets aim to replace parenteral treatments of cancer UTRECHT, Netherlands—Emilia Sawicki, a doctoral candidate at the University of Utrecht, formulated tablets of docetaxel and paclitaxel, APIs that are usually delivered intra- venously to treat prostate, breast, and lung cancer. The tablets, made from solid dispersions, increase the dissolu- tion of the treatments 40 to 100 times, and are effectively absorbed in the blood when co-administered with the enzyme inhibitor ritonavir. The new formulations enable patients to receive treatment at home instead of a hospital. Modra Pharmaceuticals, Amsterdam, Netherlands, plans to launch several clinical trials to study the docetaxel tablet. markets Serialization requirement to drive growth at contract packagers ELMHURST, IL—The growing need for pharmaceutical serialization in the USA, France, and China will drive the demand for contract pack- aging for the next 4 years, according to a report by Technavio. The report predicts the global market for phar- maceutical contract packaging will grow at a compound annual rate of more than 14 percent. Market for pharma excipients to grow more than 6 percent annually SEATTLE, WA—A rising demand for new and improved pharmaceuti- cals, development of new drug deliv- ery systems, and greater understand- ing of the functional benefits of excipients will drive growth in the global pharmaceutical excipients market. According to a report by Markets and Markets, the value of pharmaceutical excipients is forecast to reach $8.1 billion by 2021, a com- pound annual growth rate of 6.1 per- cent. The report segments the global excipient market by product, formu- lation, functionality, and region. Within the formulation segment, oral formulations accounted for the largest share of the pharmaceutical excipient market, owing to the shrinking number of new chemical entities and an increasing industry focus on developing orally disinte- grating tablets and other methods of oral drug delivery. industry news Espero, Armetheon to merge JACKSONVILLE, FL— Espero Pharmaceuticals, which manufactures cardiovascular pharmaceuticals, plans to merge with Armetheon, Menlo Park, CA. The FDA recently approved Armetheon's tecarfarin, a once-daily, oral anticoagulant treatment for patients taking warfarin. 6 May 2017 Tablets & Capsules